Should I discontinue oral Wegovy (semaglutide) after 15 days due to a new skin blister and pruritic scalp, in the absence of other systemic symptoms?

Discontinue Oral Wegovy Immediately and Evaluate for Hypersensitivity Reaction

You should stop oral Wegovy (semaglutide) immediately due to the new blister and pruritic scalp, which may represent a hypersensitivity reaction requiring prompt discontinuation. 1

Rationale for Discontinuation

The FDA label for Wegovy explicitly states that serious hypersensitivity reactions (including anaphylaxis and angioedema) have been reported with semaglutide, and the drug is contraindicated in patients with prior serious hypersensitivity reactions 1. Your presentation of a new blister combined with pruritic scalp after 15 days of therapy raises concern for an evolving dermatologic hypersensitivity reaction.

Key warning from the FDA label: "If hypersensitivity reactions occur, discontinue use of WEGOVY, treat promptly per standard of care, and monitor until signs and symptoms resolve" 1.

Why This Matters for Morbidity

While you lack systemic symptoms (no hives, respiratory distress), dermatologic hypersensitivity reactions can progress. The literature documents several patterns of semaglutide-induced skin reactions:

• Dermal hypersensitivity reactions with subepidermal blistering and eosinophils have been reported, requiring drug discontinuation for resolution 2
• Atypical pustular eruptions resembling acute generalized exanthematous pustulosis (AGEP) have occurred one month after dose escalation 3
• Drug-induced cutaneous lupus with pruritic scalp lesions and facial plaques has been documented 4
• Leukocytoclastic vasculitis with complete resolution only after discontinuation 5

Clinical Assessment Required

Look specifically for:

• Progression of blistering to other body areas
• Mucosal involvement (oral, nasal, ocular)
• Systemic symptoms: fever, malaise, joint pain
• Characteristics of the blister: size, distribution, presence of surrounding erythema or target lesions
• Scalp examination: erythema, scaling, follicular plugging, hair loss

Common Pitfall to Avoid

Do not continue the medication while "monitoring" for progression. The case series literature consistently shows that resolution occurs only after discontinuation 2, 4, 5. Continuing therapy risks progression to more severe cutaneous reactions, including Stevens-Johnson syndrome or toxic epidermal necrolysis, which have been reported with other medications in the same therapeutic context 6.

Immediate Management Steps

1. Stop oral Wegovy today - do not take another dose
2. Document the reaction with photographs if possible
3. Contact your prescribing physician within 24 hours for:
   • Clinical examination of the blister and scalp
   • Consideration of dermatology referral if lesions are extensive or atypical
   • Possible skin biopsy if diagnosis is unclear
4. Symptomatic treatment may include:
   • Oral antihistamines for pruritus
   • Topical corticosteroids if appropriate after examination
5. Monitor for progression over the next 72 hours, seeking immediate care if you develop:
   • New blisters or rash spreading
   • Facial swelling
   • Difficulty breathing or swallowing
   • Fever

Alternative Considerations

The reaction could potentially be to propylene glycol (an excipient in semaglutide formulations) rather than semaglutide itself 3. However, this distinction requires specialist evaluation and does not change the immediate recommendation to discontinue.

Rechallenge Contraindication

Do not restart semaglutide or any GLP-1 receptor agonist without explicit clearance from your physician and likely allergy/immunology consultation. The FDA label specifically warns about cross-reactivity: "Use caution in a patient with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to these reactions with WEGOVY" 1.